Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Azelis Group NV Board/Management Information 2024

May 8, 2024

3909_rns_2024-05-08_f8c13da4-86cc-4bf4-89f0-323f353ae2e3.pdf

Board/Management Information

Open in viewer

Opens in your device viewer

Biography of Kåre Schultz

Kåre Schultz

Kåre Schultz served as President and CEO of Teva Pharmaceutical Industries from 2017 until his retirement in 2023. Previously, Mr. Schultz served as President and Chief Executive Officer for H. Lundbeck A/S and worked for a large part of his career at Novo Nordisk, serving in numerous leadership roles. Mr. Schultz has been a member of several boards, including International Flavor and Fragrances and Royal Unibrew A/S, and is currently serving as Chairman of the Board for two non-listed companies, Bespak and Karo Healthcare.

Mr. Schultz holds a master's degree in economics from the University of Copenhagen.


Kåre Schultz was Voorzitter en CEO van Teva Pharmaceutical Industries van 2017 tot aan zijn pensionering in 2023. Voorheen was de heer Schultz Voorzitter en Chief Executive Officer voor H. Lundbeck A/S en werkte hij een groot deel van zijn carrière bij Novo Nordisk in tal van leidinggevende functies. De heer Schultz is lid geweest van verschillende raden van bestuur, waaronder International Flavour and Fragrances en Royal Unibrew A/S, en is momenteel Voorzitter van de raad van bestuur van twee niet-beursgenoteerde bedrijven, Bespak en Karo Healthcare.

De heer Schultz heeft een masterdiploma in economie behaald aan de Universiteit van Kopenhagen.